NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
NeurAxis, Inc. ( NRXS ) Q3 2025 Earnings Call November 11, 2025 9:00 AM EST Company Participants Brian Carrico - President, CEO & Director Timothy Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the NeurAxis Reports Third Quarter 2025 Financial Results Conference Call.
NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.
| Biotechnology Industry | Healthcare Sector | Mr. Brian Carrico CEO | AMEX Exchange | US64134X2018 ISIN |
| US Country | 19 Employees | - Last Dividend | - Last Split | 9 Aug 2023 IPO Date |
NeurAxis, Inc. is a pioneering medical technology enterprise focused on the innovation of neuromodulation therapies. These therapies are devised to alleviate chronic and debilitating conditions affecting both children and adults throughout the United States. Initially known as Innovative Health Solutions, Inc., the company underwent a name change to NeurAxis, Inc. in March 2022. Founded in 2011 and headquartered in Carmel, Indiana, NeurAxis, Inc. is at the forefront of offering groundbreaking solutions, significantly enhancing patient care. The company primarily caters to healthcare providers, including hospitals and clinics, distributing its technological advancements widely across the healthcare sector.
Listed below are the products and services offered by NeurAxis, Inc.:
This is a cutting-edge percutaneous electrical nerve field stimulation system. It's specifically designed for use in younger patients, ranging from 11 to 18 years of age, who suffer from functional abdominal pain associated with irritable bowel syndrome (IBS). The system operates by delivering targeted electrical nerve field stimulation, providing a non-pharmacological treatment option that aims to significantly reduce the symptoms of IBS in this age group. By focusing on such a niche, NeurAxis, Inc. contributes to fulfilling a critical gap in pediatric healthcare solutions.